1. Home
  2. TAVI vs ACRS Comparison

TAVI vs ACRS Comparison

Compare TAVI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TAVI
  • ACRS
  • Stock Information
  • Founded
  • TAVI 2024
  • ACRS 2012
  • Country
  • TAVI United States
  • ACRS United States
  • Employees
  • TAVI N/A
  • ACRS N/A
  • Industry
  • TAVI
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TAVI
  • ACRS Health Care
  • Exchange
  • TAVI Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • TAVI 163.0M
  • ACRS 165.7M
  • IPO Year
  • TAVI 2024
  • ACRS 2015
  • Fundamental
  • Price
  • TAVI $10.28
  • ACRS $1.70
  • Analyst Decision
  • TAVI
  • ACRS Strong Buy
  • Analyst Count
  • TAVI 0
  • ACRS 9
  • Target Price
  • TAVI N/A
  • ACRS $9.25
  • AVG Volume (30 Days)
  • TAVI 5.5K
  • ACRS 1.3M
  • Earning Date
  • TAVI 01-01-0001
  • ACRS 08-06-2025
  • Dividend Yield
  • TAVI N/A
  • ACRS N/A
  • EPS Growth
  • TAVI N/A
  • ACRS N/A
  • EPS
  • TAVI 0.12
  • ACRS N/A
  • Revenue
  • TAVI N/A
  • ACRS $17,777,000.00
  • Revenue This Year
  • TAVI N/A
  • ACRS N/A
  • Revenue Next Year
  • TAVI N/A
  • ACRS $8.11
  • P/E Ratio
  • TAVI $82.95
  • ACRS N/A
  • Revenue Growth
  • TAVI N/A
  • ACRS N/A
  • 52 Week Low
  • TAVI $9.89
  • ACRS $1.05
  • 52 Week High
  • TAVI $10.72
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • TAVI N/A
  • ACRS 65.16
  • Support Level
  • TAVI N/A
  • ACRS $1.51
  • Resistance Level
  • TAVI N/A
  • ACRS $1.78
  • Average True Range (ATR)
  • TAVI 0.00
  • ACRS 0.09
  • MACD
  • TAVI 0.00
  • ACRS 0.01
  • Stochastic Oscillator
  • TAVI 0.00
  • ACRS 76.47

About TAVI Tavia Acquisition Corp. Ordinary Shares

Tavia Acquisition Corp is a blank check company.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: